U.S. Markets closed
  • S&P 500

    4,401.46
    -20.84 (-0.47%)
     
  • Dow 30

    35,058.52
    -85.79 (-0.24%)
     
  • Nasdaq

    14,660.58
    -180.14 (-1.21%)
     
  • Russell 2000

    2,191.83
    -25.09 (-1.13%)
     
  • Crude Oil

    71.95
    +0.30 (+0.42%)
     
  • Gold

    1,799.10
    -0.70 (-0.04%)
     
  • Silver

    24.73
    +0.08 (+0.33%)
     
  • EUR/USD

    1.1822
    -0.0004 (-0.0355%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3881
    +0.0003 (+0.0194%)
     
  • USD/JPY

    109.7800
    +0.0130 (+0.0118%)
     
  • BTC-USD

    38,929.85
    +1,401.45 (+3.73%)
     
  • CMC Crypto 200

    898.78
    +22.55 (+2.57%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Seelos Therapeutics Buys Back Portion Of SLS002-Related Royalties

·1 min read
  • Seelos Therapeutics Inc (NASDAQ: SEEL) has amended the agreement with Vyera Pharmaceuticals AG, announced in March 2018, to develop SLS-002 to repurchase a significant portion of the royalties payable on any future net sales of SLS-002.

  • As additional consideration under the prior agreement, Seelos has agreed to pay a mid-teens percentage royalty on any future net sales of SLS-002. Under this amendment, for other cash payments, Seelos will repurchase 9% of the future royalties and reduce its royalty obligations to a mid-single-digit percentage on any future net sales of SLS-002.

  • Seelos has started dosing 90mg of SLS-002 in Part A of its Proof-of-Concept study in 16 patients who are imminently suicidal. Part A of the Proof-of-Concept study precedes Part B, which is a registrational double-blind placebo-controlled trial.

  • SLS-002 is intranasal racemic ketamine with two investigational new drug applications to treat acute suicidal ideation and behavior in major depressive disorder or post-traumatic stress disorder.

  • Price Action: SEEL gained 2.6% at $3.95 in premarket trading on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.